Suppr超能文献

蛋白酶疗法在进行性肾衰竭残余肾模型中的作用。

Effects of protease therapy in the remnant kidney model of progressive renal failure.

作者信息

Sebekova K, Paczek L, Dämmrich J, Ling H, Spustova V, Gaciong Z, Heidland A

机构信息

Institute of Preventive and Clinical Medicine, Bratislava, Slowakia.

出版信息

Miner Electrolyte Metab. 1997;23(3-6):291-5.

PMID:9387136
Abstract

This study investigated whether protease treatment ameliorates the progressive course of chronic failure in the rat model of subtotal nephrectomy. Fourteen male Wistar rats underwent 5/6 nephrectomy, and were randomized into a control group (C, n = 7) given 2 ml of 0.9% NaCl intraperitoneally (i.p.) daily, and a study group (P, n = 7) treated with 12 mg Phlogenzym (combination of trypsin, bromelain, and rutosid) in 2 ml saline i.p. daily. After 6 weeks treatment, the Phlogenzym group showed lower proteinuria (C: 19.6 +/- 9.1 vs. 10.2 +/- 6.2 mg/24 h, p < 0.05). Endogenous creatinine clearance was higher (C: 192.3 +/- 99.4, P: 300.5 +/- 47.9 microliters/min per 100 g, p < 0.05), while plasma creatinine was decreased (C: 106.7 +/- 33.9, P: 76.0 +/- 6.3 mumol/l, p < 0.01). Blood urea nitrogen levels did not change, although urea clearance tended to a higher level in the protease-treated rats. Decreased renal formation of cytokines was reflected by a lower urinary excretion ratio of transforming growth factor (TGF)-beta/ creatinine (C: 0.363 +/- 0.183, P: 0.232 +/- 0.085 ng TGF-beta/mg creatinine, p < 0.05). Renal morphology revealed less infiltration of mononuclear cells and an amelioration of interstitial fibrosis as expressed by the volume index of the cortical region (C: 17.17 +/- 1.43; P: 12.3 +/- 0.5%, p < 0.001). In addition, the activities of lysosomal proteinases (cathepsin B, L + B, and H), which are decreased in the remnant kidney model of chronic renal failure, were significantly higher in the enzyme-treated group both in isolated glomeruli and proximal tubules. The body and kidney weight tended to be lower, probably due to a catabolic action of the enzymes. In summary, we provide evidence that protease treatment may be beneficial in a nonimmune mediated renal disease. Phlogenzym ameliorated the course of chronic renal failure in the rat model of subtotal nephrectomy and retarded the development of tubulointerstitial fibrosis. Decreased cytokine formation in the remnant kidney is supposed to play a key role.

摘要

本研究调查了蛋白酶治疗是否能改善大鼠次全肾切除模型中慢性肾衰竭的进展过程。14只雄性Wistar大鼠接受了5/6肾切除术,并随机分为对照组(C组,n = 7),每天腹腔注射(i.p.)2 ml 0.9%氯化钠溶液,以及研究组(P组,n = 7),每天腹腔注射2 ml含12 mg Phlogenzym(胰蛋白酶、菠萝蛋白酶和芦丁的组合)的生理盐水。治疗6周后,Phlogenzym组蛋白尿较低(C组:19.6±9.1 vs. 10.2±6.2 mg/24 h,p < 0.05)。内源性肌酐清除率较高(C组:192.3±99.4,P组:300.5±47.9微升/分钟/100 g,p < 0.05),而血浆肌酐降低(C组:106.7±33.9,P组:76.0±6.3 μmol/l,p < 0.01)。血尿素氮水平未改变,尽管蛋白酶治疗的大鼠尿素清除率有升高趋势。细胞因子肾生成减少表现为转化生长因子(TGF)-β/肌酐的尿排泄率降低(C组:0.363±0.183,P组:0.232±0.085 ng TGF-β/mg肌酐,p < 0.05)。肾脏形态学显示单核细胞浸润减少,皮质区域体积指数所表示的间质纤维化有所改善(C组:17.17±1.43;P组:12.3±0.5%,p < (此处原文有误,推测应为p < 0.001))。此外,在慢性肾衰竭残余肾模型中降低的溶酶体蛋白酶(组织蛋白酶B、L + B和H)活性,在酶治疗组的分离肾小球和近端小管中均显著升高。体重和肾脏重量有降低趋势,可能是由于酶的分解代谢作用。总之,我们提供的证据表明蛋白酶治疗可能对非免疫介导的肾脏疾病有益。Phlogenzym改善了大鼠次全肾切除模型中慢性肾衰竭的病程,并延缓了肾小管间质纤维化的发展。残余肾中细胞因子生成减少被认为起关键作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验